First Trust Advisors LP Acquires 344,035 Shares of Recursion Pharmaceuticals, Inc. $RXRX

First Trust Advisors LP raised its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 15.2% in the first quarter, Holdings Channel reports. The institutional investor owned 2,610,726 shares of the company’s stock after buying an additional 344,035 shares during the quarter. First Trust Advisors LP’s holdings in Recursion Pharmaceuticals were worth $8,015,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Brighton Jones LLC increased its position in Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock worth $137,000 after acquiring an additional 6,699 shares during the period. Royal Bank of Canada raised its stake in Recursion Pharmaceuticals by 627.6% during the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock valued at $1,423,000 after purchasing an additional 232,038 shares during the last quarter. AQR Capital Management LLC bought a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Recursion Pharmaceuticals by 7.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock valued at $953,000 after purchasing an additional 12,372 shares during the period. Finally, Focus Partners Wealth bought a new stake in Recursion Pharmaceuticals in the 1st quarter valued at $77,000. 89.06% of the stock is owned by institutional investors.

Insider Activity

In other news, Director Blake Borgeson sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total transaction of $158,400.00. Following the completion of the sale, the director owned 6,218,287 shares of the company’s stock, valued at approximately $24,624,416.52. This trade represents a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the transaction, the chief executive officer owned 2,175,796 shares of the company’s stock, valued at $7,789,349.68. This trade represents a 1.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 131,937 shares of company stock worth $486,974 over the last ninety days. Insiders own 6.65% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Morgan Stanley increased their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. JPMorgan Chase & Co. decreased their target price on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Finally, Needham & Company LLC restated a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $8.10.

Recursion Pharmaceuticals Stock Down 1.3%

Shares of NASDAQ:RXRX opened at $3.00 on Friday. The company’s fifty day moving average is $3.32 and its 200-day moving average is $3.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47. Recursion Pharmaceuticals, Inc. has a 52 week low of $2.77 and a 52 week high of $7.18. The company has a market capitalization of $1.59 billion, a PE ratio of -2.50 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The business had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $15.78 million. During the same quarter last year, the company posted ($0.50) EPS. The firm’s revenue for the quarter was down 56.8% on a year-over-year basis. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -0.99 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.